Search

Your search keyword '"Tanese, Keiji"' showing total 291 results

Search Constraints

Start Over You searched for: Author "Tanese, Keiji" Remove constraint Author: "Tanese, Keiji"
291 results on '"Tanese, Keiji"'

Search Results

1. Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis

3. Multifaceted analysis of cross-tissue transcriptomes reveals phenotype–endotype associations in atopic dermatitis

5. Clinical and laboratory findings characterizing the need for systemic corticosteroids and nonsteroidal systemic therapies, and the predicted outcomes in cutaneous polyarteritis nodosa: A single-centre retrospective analysis

6. Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).

7. Cutaneous inflammatory pseudotumour of the face; does this almost forgotten disease concept still exist?

9. The role of macrophage migration inhibitory factor family and CD74 in the pathogenesis of melanoma.

12. Comprehensive Genomic Characterization of Staphylococcus aureus Isolated from Atopic Dermatitis Patients in Japan: Correlations with Disease Severity, Eruption Type, and Anatomical Site

13. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)

14. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol

15. Supplementary Table S1 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma

16. Supplemantary Figure S1 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma

17. Supplementary Material S2 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma

18. Barrier Factors of Adherence to Dupilumab Self-Injection for Severe Allergic Disease: A Non-Interventional Open-Label Study

19. Barrier Factors of Adherence to Dupilumab Self-Injection for Severe Allergic Disease: A Non-Interventional Open-Label Study

24. Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B‐PAD study)

26. Multifaceted analysis of cross-tissue, cross-sectional and longitudinal transcriptomes reveals phenotype–endotype associations in atopic dermatitis.

47. Stratification of atopic dermatitis patients by patterns of response to proactive therapy with topical tacrolimus: low serum IgE levels and inadequately controlled disease activity at the start of treatment predict its failure

Catalog

Books, media, physical & digital resources